sodium citrate/citric acid (Rx)

Brand and Other Names:Albrights Solution, Bicitra, more...Cytra 2, Oracit, Shohls Solution
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

sodium citrate/citric acid (1 mEq sodium equivalent to 1 mEq bicarbonate)

oral solution

  • (500mg/334mg)/5mL
  • (490mg/640mg)/5mL
more...

Urine Alkalinization, Prevention of Nephrolithiasis

10-30 mL diluted in up to 6 oz water/juice PO PC & HS PRN

Follow with additional water if desired

Dosage Forms & Strengths

sodium citrate/citric acid (1 mEq sodium equivalent to 1 mEq bicarbonate)

oral solution

  • (500mg/334mg)/5mL
  • (490mg/640mg)/5mL
more...

Urine Alkalinization, Prevention of Nephrolithiasis

<2 years: Based on physician's discretion

>2 years: 5-15 mL diluted in 30-90 mL of water/juice PO PC & HS PRN

Follow with additional water if desired

Next:

Interactions

Interaction Checker

and sodium citrate/citric acid

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Diarrhea

            Nausea

            Tetany

            Metabolic alkalosis

            Vomiting

            Stomach pain

            Fluid retention

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to drug or component of the formulation

            Severe renal impairment

            Sodium-restricted diet

            Cautions

            Use with caution in high BP, kidney or liver disease, cardiac failure, toxemia of pregnancy, peripheral/pulmonary edema, shock, or the severely ill

            Do not dilute in tomato juice

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: consult physician

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Alkalinizes urine; citrate binds with urinary calcium

            Pharmacokinetics

            Metabolism: Oxidized to sodium bicarbonate

            Excretion: Urine

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous